{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T23:08:42Z","timestamp":1724972922937},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s13300-013-0041-z","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T18:41:53Z","timestamp":1381344113000},"page":"399-408","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries"],"prefix":"10.1007","volume":"4","author":[{"given":"Akram","family":"Echtay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Tsur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad I.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Omar","family":"Abu-Hijleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidal","family":"Al Khatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Andari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleem","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Sandalci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asude","family":"Ademogullar\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bracha","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,10]]},"reference":[{"key":"41_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2337\/diaclin.27.2.60","volume":"27","author":"K Niswender","year":"2009","unstructured":"Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes. 2009;27:60\u20138.","journal-title":"Clin Diabetes"},{"key":"41_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577\u201396.","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"41_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc11-S011","volume":"34","author":"American Diabetes Association","year":"2011","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl. 1):S11\u201361.","journal-title":"Diabetes Care"},{"key":"41_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1056-8727(03)00058-8","volume":"18","author":"S Davis","year":"2004","unstructured":"Davis S, Alonso MD. Hypoglycemia as a barrier to glycaemic control. J Diabetes Complicat. 2004;18:60\u20138.","journal-title":"J Diabetes Complicat"},{"key":"41_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/pdi.433","volume":"20","author":"PD Home","year":"2003","unstructured":"Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int. 2003;20:63\u201371.","journal-title":"Pract Diabetes Int"},{"key":"41_CR6","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1007\/s00125-005-1916-y","volume":"48","author":"HE Scholtz","year":"2005","unstructured":"Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988\u201395.","journal-title":"Diabetologia"},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2165\/11470200-000000000-00000","volume":"72","author":"GM Keating","year":"2012","unstructured":"Keating GM. Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs. 2012;72:2255\u201387.","journal-title":"Drugs"},{"key":"41_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1464-5491.2006.01847.x","volume":"23","author":"JB Ferriss","year":"2006","unstructured":"Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B, EURODIAB Prospective Complications Group. Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in type 1 diabetes. Diabet Med. 2006;23:557\u201364.","journal-title":"Diabet Med"},{"key":"41_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2337\/diacare.28.5.1107","volume":"28","author":"J Plank","year":"2005","unstructured":"Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107\u201312.","journal-title":"Diabetes Care"},{"key":"41_CR10","first-page":"16","volume":"57","author":"C Mathieu","year":"2009","unstructured":"Mathieu C. Engineering basal insulin\u2014clinical evidence translating to clinical experience. JAPI. 2009;57:16\u201321.","journal-title":"JAPI"},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.diabres.2004.03.003","volume":"66","author":"K Raslova","year":"2004","unstructured":"Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193\u2013201.","journal-title":"Diabetes Res Clin Pract"},{"key":"41_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1463-1326.2004.00373.x","volume":"7","author":"T Haak","year":"2005","unstructured":"Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1463-1326.2012.01665.x","volume":"14","author":"on behalf of the SOLVE Study Group","year":"2012","unstructured":"Khunti K, Caputo S, Damci T, et al; on behalf of the SOLVE Study Group. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012;14:1129\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1742-1241.2008.01715.x","volume":"62","author":"PREDICTIVE Study Group","year":"2008","unstructured":"Dornhorst A, L\u00fcddeke HJ, Sreenan S, et al; PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-na\u00efve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62:659\u201365.","journal-title":"Int J Clin Pract"},{"key":"41_CR15","unstructured":"Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium; 2011, updated 14 November 2012. \n                    http:\/\/www.idf.org\/diabetesatlas\/5e\n                    \n                  . Accessed 23 September 2013."},{"key":"41_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"DR Whiting","year":"2011","unstructured":"Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311\u201321.","journal-title":"Diabetes Res Clin Pract"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"American Diabetes Association; European Association for Study of Diabetes","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193\u2013203.","journal-title":"Diabetes Care"},{"issue":"3","key":"41_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1900\/RDS.2008.5.154","volume":"5","author":"L Breum","year":"2008","unstructured":"Breum L, Almdal T, Eiken P, Lund P, Christiansen E, Danish BIAsp Study Group. Initiating or switching to biphasic insulin aspart 30\/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud. 2008;5(3):154\u201362.","journal-title":"Rev Diabet Stud"},{"issue":"3","key":"41_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","volume":"51","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408\u201316.","journal-title":"Diabetologia"},{"issue":"6","key":"41_CR20","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.2337\/dc09-2294","volume":"33","author":"SG Swinnen","year":"2010","unstructured":"Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33(6):1176\u20138.","journal-title":"Diabetes Care"},{"key":"41_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s001250051172","volume":"42","author":"S M\u00e4kimattila","year":"1999","unstructured":"M\u00e4kimattila S, Nikkil\u00e4 K, Yki-J\u00e4rvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999;42:406\u201312.","journal-title":"Diabetologia"},{"key":"41_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2165\/00044011-200727040-00007","volume":"27","author":"K Raslov\u00e1","year":"2007","unstructured":"Raslov\u00e1 K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27:279\u201385.","journal-title":"Clin Drug Investig"},{"key":"41_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1463-1326.2006.00665.x","volume":"9","author":"K Hermansen","year":"2007","unstructured":"Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9:209\u201317.","journal-title":"Diabetes Obes Metab"},{"key":"41_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/DMSOTT.S3401","volume":"2","author":"GE Peterson","year":"2009","unstructured":"Peterson GE. Analog insulin detemir for patients with type 1 and type 2 diabetes: a review. Diabetes Metab Syndr Obes. 2009;2:31\u20136.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"41_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/diacare.25.2.330","volume":"25","author":"A Wright","year":"2002","unstructured":"Wright A, Burden ACF, Paisey RB, Cill CA, Holman RR, and the UK Prospective Diabetes Study Group. Sulphonylurea inadequacy: efficacy of addition of insulin over 6\u00a0years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330\u20136.","journal-title":"Diabetes Care"},{"key":"41_CR26","first-page":"457","volume":"13","author":"AA Riedel","year":"2007","unstructured":"Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulphonylurea therapy to metformin regimen. Am J Manag Care. 2007;13:457\u201363.","journal-title":"Am J Manag Care"},{"issue":"6","key":"41_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2337\/dc05-1365","volume":"29","author":"K Hermansen","year":"2006","unstructured":"Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269\u201374.","journal-title":"Diabetes Care"},{"key":"41_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1503\/cmaj.051484","volume":"174","author":"JP Vandenbroucke","year":"2006","unstructured":"Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ. 2006;174:645\u20136.","journal-title":"CMAJ"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-013-0041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-013-0041-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-013-0041-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-013-0041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T14:46:15Z","timestamp":1548081975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-013-0041-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s13300-013-0041-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,10]]}}}